Friday, October 10, 2003
8:00 - 9:35 am Session I: Angiogenesis & the Metastatic Process as Targets for Therapeutic Development–Part A
Session Chair: Dr. Jonathan Simons

1. VEGF/HIF and Angiogenesis in Malignancies - Dr. Jonathan Simons
2. CNTO 95 – Human Monoclonal Antibody to alpha v - Dr. Mohit Trikha
3. Targeting VEGF with Bevacizumab – Clinical Results in Colorectal Cancer - Dr. Fairooz Kabbinavar

9:35 - 11:15 am Session II: Angiogenesis & the Metastatic Process as Targets for Therapeutic
Development–Part B
Session Chair: Dr. William Boyle

1. Basic Biology of the Metastatic Process - Dr. Ann Chambers
2. The PI-3 Kinase Pathway in Metastasis - Dr. M. Jane Arboleda
3. A Molecular Portrait of Breast Cancer Metastasis to the Brain - Dr. Patricia Steeg
4. The OPG Pathway in Bone Disease and Metastasis - Dr. William Boyle

12:30 - 2:05 pm Session III: Biologic Imaging Markers and Predictive/Prognostic Factors
Session Chair: Dr. Michael Press

1. Biologic and Molecular Imaging: Animals to Humans - Dr. Johannes Czernin
2. Testing for HER-2 and Lessons Learned - Dr. Michael Press
3. Mammaglobin: A Breast-Specific Marker? - Dr. Joseph Duffy
4. COX-2 as a Target in Cancer - Dr. Raymond duBois

Saturday, October 11, 2003
8:00 - 9:45 am Session IV: Growth Factors and Growth Factor Receptors as Targets
Session Chair: Dr. John Crown

1. HER-1/HER-2 Targeting in Human Malignancies - Dr. Stephen Kelsey
2. Process on HER-2 Tyrosine Kinase Inhibition - Dr. Louis Denis
3. A Pre-Clinical Evaluation of a Novel Dual Kinase Inhibitor: GW572016 in Breast Cancer - Dr. Gottfried Konecny
4. A Dual HER-1/HER-2 Kinase Inhibitor - Dr. Stephen Rubin
5. Cetuximab Pharmacogenomics - Dr. David Mauro
   
6. Metronomic Chemotherapy: Molecular Mechanisms and Integration - Dr. Robert Kerbel
   

10:35 - 2:00 pm Session V: Signal Transduction and Cell Cycle Pathways as Targets
Session Chair: Dr. Fuyuhiko Tamanoi

1. Prodrug Strategy Targeting Drug Resistant Colorectal Cancer - Dr. Mark Pegram
2. PKC-Signaling in Human Cancer: Potential as a Target - Dr. Donald Thornton
3. A Novel Cell Cycle Inhibitor for Treating Cancer - Dr. Roberto Weinmann
4. Development of Novel Inhibitors of the Ras Signaling Pathway - Dr. Fuyuhiko Tamanoi
5. A Novel Tyrosine Kinase Inhibitor-SU11248 - Dr. Laurie Strawn
6. CNTO 328 – An Antibody to Interleukin 6 in Tumor Progression - Dr. Mohit Trikha

2:00 - 3:35 pm Session VI: New Approaches to Established Targets/Pathways
Session Chair: Dr. Fran Visco

1. Targeted Research: The Patient’s Perspective - Dr. Fran Visco
2. Receptor Tyrosine Kinases and Breast Cancer - Dr. Cindy Wilson
3. Targeting the bcr/abl gene: Mechanism of Resistance to Imatinib - Dr. Neil Shah
4. Proteasome Inhibitors: Basic Biology and Early Clinical Experience - Dr. Mark Rolfe

Sunday, October 12, 2003
8:00 - 9:35 am Session VII: Target Pathway Identification in Cancer Treatment
Session Chair: Dr. Dennis Slamon

1. Pemetrexed Development - Dr. Hilary Calvert
2. Targets in Melanoma - Dr. John Glaspy
3. Combined Therapeutic Approaches Using Signaling Biology - Dr. Dennis Slamon

9:35 - 10:30 am Session VIII: Steroid Hormonal Receptors and Manipulation in the Treatment of Cancer
Session Chair: Dr. Anthony Howell

1. Aromatase Inhibitors and Role of Anti-Estrogen in Breast Cancer - Dr. Anthony Howell
2. Combination Therapy Using Hormone and Peptide Signaling Pathways - Dr. Richard Pietras

10:30 - 11:20 am Session IX: Apoptosis as a Target in Malignancies
Session Chair: Dr. Dale Ludwig

1. The IGF-1 Receptor as a Therapeutic Target - Dr. Dale Ludwig
2. Surviving as a Target in Cancer - Dr. Bharvin Patel